Previous malignancy is an independent predictor of follow‐up mortality after percutaneous treatment of mitral valve regurgitation by means of MitraClip
Summary Aims To investigate the prognostic burden of previously diagnosed and treated malignancies in candidates for percutaneous mitral valve repair (MVR) with MitraClip. Methods and Results A total of 165 patients underwent MVR and 19 (11.5%) had been previously treated for malignancy and consider...
Gespeichert in:
| Veröffentlicht in: | Cardiovascular therapeutics 2017-04, Vol.35 (2), p.n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 2 |
| container_start_page | |
| container_title | Cardiovascular therapeutics |
| container_volume | 35 |
| creator | Öner, Alper Ince, Hüseyin Paranskaya, Liliya Schröder, Guido Sherif, Mohammad Thiele, Olga Neuhausen, Alla Kische, Stephan Ortak, Jasmin D′Ancona, Giuseppe |
| description | Summary
Aims
To investigate the prognostic burden of previously diagnosed and treated malignancies in candidates for percutaneous mitral valve repair (MVR) with MitraClip.
Methods and Results
A total of 165 patients underwent MVR and 19 (11.5%) had been previously treated for malignancy and considered healed with life expectancy over 1 year at time of percutaneous MVR. There was a significant trend for an increased overall risk profile (euroSCORE II 14.0±11.4 vs 10.0±6.7, P=.01) in patients with a previous diagnosis of neoplasia. Moreover, neoplastic patients had lower device success rates (78.9% vs 97.3%; P=.001), longer hospitalization (12.3±10.6 vs 7.5±4.9 days, P=.001), and higher 30‐day mortality (10.5% vs 2.7%, P=.09). Kaplan‐Meier overall estimated 1‐, 2‐, 3‐, and 4‐year survival of the overall cohort was 72%, 61%, 48%, and 44%, respectively. Estimated 1‐ and 2‐year survival were 44.4% and 22.2 % in patients with previous neoplasia and 75.3% and 65% in the remaining patients (P |
| doi_str_mv | 10.1111/1755-5922.12239 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_24P</sourceid><recordid>TN_cdi_proquest_miscellaneous_1852690472</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1852690472</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4129-8498af59743ff78137b6bf8dd9f0367375f308f5b7fff4e2a54db202c230a15f3</originalsourceid><addsrcrecordid>eNqFkc2O1SAYhhujccbRtTtD4sbNmQEKpSzN8TcZozG6JrT9OGFCoQI9k-68BLfenlciteNZuJEFEHjeJ5C3qp4SfEnKuCKC8x2XlF4SSmt5rzo_ndw_7Qk7qx6ldINxg2VDHlZnVMhWUEHOq5-fIhxtmBMatbMHr32_IJuQ9sj6ASYok89oijDYPoeIgkEmOBduf33_MU9oDDGXYF6QNhkimiD2c9YeVmWOoPO45ktqtDlqh47aHQFFOMzxYLPONnjULWgE7dOKfVixvbPT4-qB0S7Bk7v1ovr65vWX_bvd9ce37_cvr3c9I1TuWiZbbbgUrDZGtKQWXdOZdhikwXUjasFNjVvDO2GMYUA1Z0NHMe1pjTUplxfVi807xfBthpTVaFMPzm2fUKTltJGYCVrQ5_-gN2GOvryuUKJhDaMCF-pqo_oYUopg1BTtqOOiCFZra2rtRa0dqT-tlcSzO-_cjTCc-L81FYBvwK11sPzPp_avPm_i30i5pWA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1876464270</pqid></control><display><type>article</type><title>Previous malignancy is an independent predictor of follow‐up mortality after percutaneous treatment of mitral valve regurgitation by means of MitraClip</title><source>Wiley Online Library Open Access</source><creator>Öner, Alper ; Ince, Hüseyin ; Paranskaya, Liliya ; Schröder, Guido ; Sherif, Mohammad ; Thiele, Olga ; Neuhausen, Alla ; Kische, Stephan ; Ortak, Jasmin ; D′Ancona, Giuseppe</creator><creatorcontrib>Öner, Alper ; Ince, Hüseyin ; Paranskaya, Liliya ; Schröder, Guido ; Sherif, Mohammad ; Thiele, Olga ; Neuhausen, Alla ; Kische, Stephan ; Ortak, Jasmin ; D′Ancona, Giuseppe</creatorcontrib><description>Summary
Aims
To investigate the prognostic burden of previously diagnosed and treated malignancies in candidates for percutaneous mitral valve repair (MVR) with MitraClip.
Methods and Results
A total of 165 patients underwent MVR and 19 (11.5%) had been previously treated for malignancy and considered healed with life expectancy over 1 year at time of percutaneous MVR. There was a significant trend for an increased overall risk profile (euroSCORE II 14.0±11.4 vs 10.0±6.7, P=.01) in patients with a previous diagnosis of neoplasia. Moreover, neoplastic patients had lower device success rates (78.9% vs 97.3%; P=.001), longer hospitalization (12.3±10.6 vs 7.5±4.9 days, P=.001), and higher 30‐day mortality (10.5% vs 2.7%, P=.09). Kaplan‐Meier overall estimated 1‐, 2‐, 3‐, and 4‐year survival of the overall cohort was 72%, 61%, 48%, and 44%, respectively. Estimated 1‐ and 2‐year survival were 44.4% and 22.2 % in patients with previous neoplasia and 75.3% and 65% in the remaining patients (P<.0001). Median survival was 312 days in the neoplastic group (CI 95%: 182.6‐441.4 days) and 1209 days in the remaining patients (CI 95%: 758.8‐1659.2 days) (P<.0001). At Cox regression, the strongest determinant for mortality was an anamnesis for neoplasia (HR 2.4, 95% CI 1.4‐4.3, P=.001).
Conclusions
Previous neoplasm is a significant independent predictor of increased mortality after MVR with MitraClip. This association is even stronger than that of other cardiac and overall comorbidities and should be kept into consideration when referring patients for treatment.</description><identifier>ISSN: 1755-5914</identifier><identifier>EISSN: 1755-5922</identifier><identifier>DOI: 10.1111/1755-5922.12239</identifier><identifier>PMID: 27987271</identifier><language>eng</language><publisher>England: Hindawi Limited</publisher><subject>Aged ; Aged, 80 and over ; Cardiac Catheterization - adverse effects ; Cardiac Catheterization - instrumentation ; Cardiac Catheterization - mortality ; Chi-Square Distribution ; Databases, Factual ; Echocardiography ; Female ; Humans ; Kaplan-Meier Estimate ; Length of Stay ; Logistic Models ; Male ; Mitral Regurgitation ; Mitral valve ; Mitral Valve - diagnostic imaging ; Mitral Valve - physiopathology ; Mitral Valve Insufficiency - diagnostic imaging ; Mitral Valve Insufficiency - mortality ; Mitral Valve Insufficiency - physiopathology ; Mitral Valve Insufficiency - therapy ; Multivariate Analysis ; Neoplasia ; Neoplasms - diagnosis ; Neoplasms - mortality ; Neoplasms - therapy ; Percutaneous intervention ; Proportional Hazards Models ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Time Factors ; Treatment Outcome</subject><ispartof>Cardiovascular therapeutics, 2017-04, Vol.35 (2), p.n/a</ispartof><rights>2016 John Wiley & Sons Ltd</rights><rights>2016 John Wiley & Sons Ltd.</rights><rights>Copyright © 2017 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4129-8498af59743ff78137b6bf8dd9f0367375f308f5b7fff4e2a54db202c230a15f3</citedby><cites>FETCH-LOGICAL-c4129-8498af59743ff78137b6bf8dd9f0367375f308f5b7fff4e2a54db202c230a15f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2F1755-5922.12239$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2F1755-5922.12239$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1433,11562,27924,27925,46052,46409,46476,46833</link.rule.ids><linktorsrc>$$Uhttps://onlinelibrary.wiley.com/doi/abs/10.1111%2F1755-5922.12239$$EView_record_in_Wiley-Blackwell$$FView_record_in_$$GWiley-Blackwell</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27987271$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Öner, Alper</creatorcontrib><creatorcontrib>Ince, Hüseyin</creatorcontrib><creatorcontrib>Paranskaya, Liliya</creatorcontrib><creatorcontrib>Schröder, Guido</creatorcontrib><creatorcontrib>Sherif, Mohammad</creatorcontrib><creatorcontrib>Thiele, Olga</creatorcontrib><creatorcontrib>Neuhausen, Alla</creatorcontrib><creatorcontrib>Kische, Stephan</creatorcontrib><creatorcontrib>Ortak, Jasmin</creatorcontrib><creatorcontrib>D′Ancona, Giuseppe</creatorcontrib><title>Previous malignancy is an independent predictor of follow‐up mortality after percutaneous treatment of mitral valve regurgitation by means of MitraClip</title><title>Cardiovascular therapeutics</title><addtitle>Cardiovasc Ther</addtitle><description>Summary
Aims
To investigate the prognostic burden of previously diagnosed and treated malignancies in candidates for percutaneous mitral valve repair (MVR) with MitraClip.
Methods and Results
A total of 165 patients underwent MVR and 19 (11.5%) had been previously treated for malignancy and considered healed with life expectancy over 1 year at time of percutaneous MVR. There was a significant trend for an increased overall risk profile (euroSCORE II 14.0±11.4 vs 10.0±6.7, P=.01) in patients with a previous diagnosis of neoplasia. Moreover, neoplastic patients had lower device success rates (78.9% vs 97.3%; P=.001), longer hospitalization (12.3±10.6 vs 7.5±4.9 days, P=.001), and higher 30‐day mortality (10.5% vs 2.7%, P=.09). Kaplan‐Meier overall estimated 1‐, 2‐, 3‐, and 4‐year survival of the overall cohort was 72%, 61%, 48%, and 44%, respectively. Estimated 1‐ and 2‐year survival were 44.4% and 22.2 % in patients with previous neoplasia and 75.3% and 65% in the remaining patients (P<.0001). Median survival was 312 days in the neoplastic group (CI 95%: 182.6‐441.4 days) and 1209 days in the remaining patients (CI 95%: 758.8‐1659.2 days) (P<.0001). At Cox regression, the strongest determinant for mortality was an anamnesis for neoplasia (HR 2.4, 95% CI 1.4‐4.3, P=.001).
Conclusions
Previous neoplasm is a significant independent predictor of increased mortality after MVR with MitraClip. This association is even stronger than that of other cardiac and overall comorbidities and should be kept into consideration when referring patients for treatment.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Cardiac Catheterization - adverse effects</subject><subject>Cardiac Catheterization - instrumentation</subject><subject>Cardiac Catheterization - mortality</subject><subject>Chi-Square Distribution</subject><subject>Databases, Factual</subject><subject>Echocardiography</subject><subject>Female</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Length of Stay</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Mitral Regurgitation</subject><subject>Mitral valve</subject><subject>Mitral Valve - diagnostic imaging</subject><subject>Mitral Valve - physiopathology</subject><subject>Mitral Valve Insufficiency - diagnostic imaging</subject><subject>Mitral Valve Insufficiency - mortality</subject><subject>Mitral Valve Insufficiency - physiopathology</subject><subject>Mitral Valve Insufficiency - therapy</subject><subject>Multivariate Analysis</subject><subject>Neoplasia</subject><subject>Neoplasms - diagnosis</subject><subject>Neoplasms - mortality</subject><subject>Neoplasms - therapy</subject><subject>Percutaneous intervention</subject><subject>Proportional Hazards Models</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>1755-5914</issn><issn>1755-5922</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc2O1SAYhhujccbRtTtD4sbNmQEKpSzN8TcZozG6JrT9OGFCoQI9k-68BLfenlciteNZuJEFEHjeJ5C3qp4SfEnKuCKC8x2XlF4SSmt5rzo_ndw_7Qk7qx6ldINxg2VDHlZnVMhWUEHOq5-fIhxtmBMatbMHr32_IJuQ9sj6ASYok89oijDYPoeIgkEmOBduf33_MU9oDDGXYF6QNhkimiD2c9YeVmWOoPO45ktqtDlqh47aHQFFOMzxYLPONnjULWgE7dOKfVixvbPT4-qB0S7Bk7v1ovr65vWX_bvd9ce37_cvr3c9I1TuWiZbbbgUrDZGtKQWXdOZdhikwXUjasFNjVvDO2GMYUA1Z0NHMe1pjTUplxfVi807xfBthpTVaFMPzm2fUKTltJGYCVrQ5_-gN2GOvryuUKJhDaMCF-pqo_oYUopg1BTtqOOiCFZra2rtRa0dqT-tlcSzO-_cjTCc-L81FYBvwK11sPzPp_avPm_i30i5pWA</recordid><startdate>201704</startdate><enddate>201704</enddate><creator>Öner, Alper</creator><creator>Ince, Hüseyin</creator><creator>Paranskaya, Liliya</creator><creator>Schröder, Guido</creator><creator>Sherif, Mohammad</creator><creator>Thiele, Olga</creator><creator>Neuhausen, Alla</creator><creator>Kische, Stephan</creator><creator>Ortak, Jasmin</creator><creator>D′Ancona, Giuseppe</creator><general>Hindawi Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201704</creationdate><title>Previous malignancy is an independent predictor of follow‐up mortality after percutaneous treatment of mitral valve regurgitation by means of MitraClip</title><author>Öner, Alper ; Ince, Hüseyin ; Paranskaya, Liliya ; Schröder, Guido ; Sherif, Mohammad ; Thiele, Olga ; Neuhausen, Alla ; Kische, Stephan ; Ortak, Jasmin ; D′Ancona, Giuseppe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4129-8498af59743ff78137b6bf8dd9f0367375f308f5b7fff4e2a54db202c230a15f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Cardiac Catheterization - adverse effects</topic><topic>Cardiac Catheterization - instrumentation</topic><topic>Cardiac Catheterization - mortality</topic><topic>Chi-Square Distribution</topic><topic>Databases, Factual</topic><topic>Echocardiography</topic><topic>Female</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Length of Stay</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Mitral Regurgitation</topic><topic>Mitral valve</topic><topic>Mitral Valve - diagnostic imaging</topic><topic>Mitral Valve - physiopathology</topic><topic>Mitral Valve Insufficiency - diagnostic imaging</topic><topic>Mitral Valve Insufficiency - mortality</topic><topic>Mitral Valve Insufficiency - physiopathology</topic><topic>Mitral Valve Insufficiency - therapy</topic><topic>Multivariate Analysis</topic><topic>Neoplasia</topic><topic>Neoplasms - diagnosis</topic><topic>Neoplasms - mortality</topic><topic>Neoplasms - therapy</topic><topic>Percutaneous intervention</topic><topic>Proportional Hazards Models</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Öner, Alper</creatorcontrib><creatorcontrib>Ince, Hüseyin</creatorcontrib><creatorcontrib>Paranskaya, Liliya</creatorcontrib><creatorcontrib>Schröder, Guido</creatorcontrib><creatorcontrib>Sherif, Mohammad</creatorcontrib><creatorcontrib>Thiele, Olga</creatorcontrib><creatorcontrib>Neuhausen, Alla</creatorcontrib><creatorcontrib>Kische, Stephan</creatorcontrib><creatorcontrib>Ortak, Jasmin</creatorcontrib><creatorcontrib>D′Ancona, Giuseppe</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Cardiovascular therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Öner, Alper</au><au>Ince, Hüseyin</au><au>Paranskaya, Liliya</au><au>Schröder, Guido</au><au>Sherif, Mohammad</au><au>Thiele, Olga</au><au>Neuhausen, Alla</au><au>Kische, Stephan</au><au>Ortak, Jasmin</au><au>D′Ancona, Giuseppe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Previous malignancy is an independent predictor of follow‐up mortality after percutaneous treatment of mitral valve regurgitation by means of MitraClip</atitle><jtitle>Cardiovascular therapeutics</jtitle><addtitle>Cardiovasc Ther</addtitle><date>2017-04</date><risdate>2017</risdate><volume>35</volume><issue>2</issue><epage>n/a</epage><issn>1755-5914</issn><eissn>1755-5922</eissn><abstract>Summary
Aims
To investigate the prognostic burden of previously diagnosed and treated malignancies in candidates for percutaneous mitral valve repair (MVR) with MitraClip.
Methods and Results
A total of 165 patients underwent MVR and 19 (11.5%) had been previously treated for malignancy and considered healed with life expectancy over 1 year at time of percutaneous MVR. There was a significant trend for an increased overall risk profile (euroSCORE II 14.0±11.4 vs 10.0±6.7, P=.01) in patients with a previous diagnosis of neoplasia. Moreover, neoplastic patients had lower device success rates (78.9% vs 97.3%; P=.001), longer hospitalization (12.3±10.6 vs 7.5±4.9 days, P=.001), and higher 30‐day mortality (10.5% vs 2.7%, P=.09). Kaplan‐Meier overall estimated 1‐, 2‐, 3‐, and 4‐year survival of the overall cohort was 72%, 61%, 48%, and 44%, respectively. Estimated 1‐ and 2‐year survival were 44.4% and 22.2 % in patients with previous neoplasia and 75.3% and 65% in the remaining patients (P<.0001). Median survival was 312 days in the neoplastic group (CI 95%: 182.6‐441.4 days) and 1209 days in the remaining patients (CI 95%: 758.8‐1659.2 days) (P<.0001). At Cox regression, the strongest determinant for mortality was an anamnesis for neoplasia (HR 2.4, 95% CI 1.4‐4.3, P=.001).
Conclusions
Previous neoplasm is a significant independent predictor of increased mortality after MVR with MitraClip. This association is even stronger than that of other cardiac and overall comorbidities and should be kept into consideration when referring patients for treatment.</abstract><cop>England</cop><pub>Hindawi Limited</pub><pmid>27987271</pmid><doi>10.1111/1755-5922.12239</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 1755-5914 |
| ispartof | Cardiovascular therapeutics, 2017-04, Vol.35 (2), p.n/a |
| issn | 1755-5914 1755-5922 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1852690472 |
| source | Wiley Online Library Open Access |
| subjects | Aged Aged, 80 and over Cardiac Catheterization - adverse effects Cardiac Catheterization - instrumentation Cardiac Catheterization - mortality Chi-Square Distribution Databases, Factual Echocardiography Female Humans Kaplan-Meier Estimate Length of Stay Logistic Models Male Mitral Regurgitation Mitral valve Mitral Valve - diagnostic imaging Mitral Valve - physiopathology Mitral Valve Insufficiency - diagnostic imaging Mitral Valve Insufficiency - mortality Mitral Valve Insufficiency - physiopathology Mitral Valve Insufficiency - therapy Multivariate Analysis Neoplasia Neoplasms - diagnosis Neoplasms - mortality Neoplasms - therapy Percutaneous intervention Proportional Hazards Models Retrospective Studies Risk Assessment Risk Factors Time Factors Treatment Outcome |
| title | Previous malignancy is an independent predictor of follow‐up mortality after percutaneous treatment of mitral valve regurgitation by means of MitraClip |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T12%3A51%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_24P&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Previous%20malignancy%20is%20an%20independent%20predictor%20of%20follow%E2%80%90up%20mortality%20after%20percutaneous%20treatment%20of%20mitral%20valve%20regurgitation%20by%20means%20of%20MitraClip&rft.jtitle=Cardiovascular%20therapeutics&rft.au=%C3%96ner,%20Alper&rft.date=2017-04&rft.volume=35&rft.issue=2&rft.epage=n/a&rft.issn=1755-5914&rft.eissn=1755-5922&rft_id=info:doi/10.1111/1755-5922.12239&rft_dat=%3Cproquest_24P%3E1852690472%3C/proquest_24P%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1876464270&rft_id=info:pmid/27987271&rfr_iscdi=true |